GlassScriptPhysician profile
Padma Vellanki
NPI 1578523932
$10,018.26
in general payments reported to CMS, 2019-2025
33 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $784 · 2021: $1,282 · 2022: $1,566 · 2023: $1,601 · 2024: $1,673 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,444 · Education: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,444.04 |
| Education | $467.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,000.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,932.03 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $1,101.46 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Pfizer INC. | $827.06 | 2019-2025 | |
| Lilly USA, LLC | $496.70 | 2019-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $462.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $459.40 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.95 | 2020-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $349.48 | 2021-2023 | Lupkynis |
| Ucb, INC. | $327.04 | 2019-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $272.99 | 2019-2025 | Actemra, Gazyva |
| Astrazeneca Pharmaceuticals LP | $208.19 | 2021-2024 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $201.95 | 2019-2024 | Opsumit |
| Alkermes, INC. | $120.57 | 2019 | |
| Mallinckrodt Enterprises LLC | $114.13 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $114.05 | 2019-2025 | Benlysta |
| United Therapeutics Corporation | $86.10 | 2023 | |
| Janssen Scientific Affairs, LLC | $78.61 | 2025 | Tremfya |
| Horizon Therapeutics Plc | $60.83 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $54.82 | 2021-2024 | Acthar |
| Biocon Biologics INC | $42.92 | 2023-2024 | Hulio |
| Fidia Pharma USA INC. | $40.31 | 2019-2025 | Hymovis, Triluron |
| Regeneron Healthcare Solutions, INC. | $36.74 | 2019 | |
| Invivyd INC | $25.35 | 2025 | Pemgarda |
| Medtronic, INC. | $23.41 | 2023 | Intellis Adaptivestim |
| Sandoz INC. | $22.27 | 2023 | Hyrimoz |
| Lundbeck LLC | $21.23 | 2022 | |
| Genzyme Corporation | $19.03 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.49 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.94 | 2023 | Zilretta, Iovera |
| Sobi, INC | $16.14 | 2025 | |
| Bioventus LLC | $15.82 | 2025 | Durolane |
| Kyowa Kirin, INC. | $15.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Vellanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.